M R Patel1, M Nana2, M Yotebieng1, M Tabala2, F Behets1, A Van Rie1. 1. Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2. School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of Congo.
Abstract
SETTING: Five primary health care clinics in Kinshasa, Democratic Republic of Congo. OBJECTIVE: To examine timing and predictors of delayed initiation of antiretroviral therapy (ART) during anti-tuberculosis treatment. DESIGN: Prospective observational cohort of adult patients receiving integrated treatment for tuberculosis (TB) and human immunodeficiency virus (HIV) who are expected to initiate ART at 1 month if CD4 count is <100 cells/mm(3) or if patient is World Health Organization (WHO) Clinical Stage 4 for reasons other than extra-pulmonary TB, at 2 months if CD4 count is 100-350 cells/mm(3), or at completion of anti-tuberculosis treatment if subsequently CD4 count is ≤ 350 cells/mm(3) or patient has WHO Clinical Stage 4. RESULTS: Of 492 patients, 235 (47.8%) experienced delayed initiation of ART: 171 (72.8%) initiated ART late, after a median delay of 12 days (interquartile range [IQR] 4-27) and 64 (27.2%) never initiated ART. Contraindication to any antiretroviral drug (aOR 2.91, 95%CI 1.22-6.95), lower baseline CD4 count (aOR 1.20, 95%CI 1.08-1.33/100 cells/mm(3)), TB drug intolerance (aOR 1.93, 95%CI 1.23-3.02) and non-disclosure of HIV infection (aOR 1.50, 95%CI 1.03-2.18) predicted delayed ART initiation. CONCLUSION: Despite fully integrated treatment, half of all patients experienced delayed ART initiation. Pragmatic approaches to ensure timely ART initiation in those at risk of delayed ART initiation are needed.
SETTING: Five primary health care clinics in Kinshasa, Democratic Republic of Congo. OBJECTIVE: To examine timing and predictors of delayed initiation of antiretroviral therapy (ART) during anti-tuberculosis treatment. DESIGN: Prospective observational cohort of adult patients receiving integrated treatment for tuberculosis (TB) and human immunodeficiency virus (HIV) who are expected to initiate ART at 1 month if CD4 count is <100 cells/mm(3) or if patient is World Health Organization (WHO) Clinical Stage 4 for reasons other than extra-pulmonary TB, at 2 months if CD4 count is 100-350 cells/mm(3), or at completion of anti-tuberculosis treatment if subsequently CD4 count is ≤ 350 cells/mm(3) or patient has WHO Clinical Stage 4. RESULTS: Of 492 patients, 235 (47.8%) experienced delayed initiation of ART: 171 (72.8%) initiated ART late, after a median delay of 12 days (interquartile range [IQR] 4-27) and 64 (27.2%) never initiated ART. Contraindication to any antiretroviral drug (aOR 2.91, 95%CI 1.22-6.95), lower baseline CD4 count (aOR 1.20, 95%CI 1.08-1.33/100 cells/mm(3)), TB drug intolerance (aOR 1.93, 95%CI 1.23-3.02) and non-disclosure of HIV infection (aOR 1.50, 95%CI 1.03-2.18) predicted delayed ART initiation. CONCLUSION: Despite fully integrated treatment, half of all patients experienced delayed ART initiation. Pragmatic approaches to ensure timely ART initiation in those at risk of delayed ART initiation are needed.
Authors: Helena Legido-Quigley; Catherine M Montgomery; Palwasha Khan; Rifat Atun; Ade Fakoya; Haileyesus Getahun; Alison D Grant Journal: Trop Med Int Health Date: 2012-12-10 Impact factor: 2.622
Authors: Stephen D Lawn; Lucy Campbell; Richard Kaplan; Andrew Boulle; Morna Cornell; Bernhard Kerschberger; Carl Morrow; Francesca Little; Matthias Egger; Robin Wood Journal: J Acquir Immune Defic Syndr Date: 2011-06-01 Impact factor: 3.731
Authors: Munyaradzi Dimairo; Peter MacPherson; Tsitsi Bandason; Abbas Zezai; Shungu S Munyati; Anthony E Butterworth; Stanley Mungofa; Simba Rusikaniko; Katherine Fielding; Peter R Mason; Elizabeth L Corbett Journal: PLoS One Date: 2010-07-28 Impact factor: 3.240
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: James G Carlucci; Meridith Blevins Peratikos; Aaron M Kipp; Mary L Lindegren; Quy T Du; Lorna Renner; Gary Reubenson; John Ssali; Marcel Yotebieng; Anna M Mandalakas; Mary-Ann Davies; Marie Ballif; Lukas Fenner; April C Pettit Journal: J Acquir Immune Defic Syndr Date: 2017-06-01 Impact factor: 3.731
Authors: Sarah M Burnett; Stella Zawedde-Muyanja; Sabine M Hermans; Marcia R Weaver; Robert Colebunders; Yukari C Manabe Journal: J Acquir Immune Defic Syndr Date: 2018-12-15 Impact factor: 3.731
Authors: Marcos C Schechter; Destani Bizune; Michelle Kagei; David P Holland; Carlos Del Rio; Aliya Yamin; Omar Mohamed; Alawode Oladele; Yun F Wang; Paulina A Rebolledo; Susan M Ray; Russell R Kempker Journal: Open Forum Infect Dis Date: 2018-03-21 Impact factor: 3.835